ORLANDO, Fla. — Some Medicare recipients will soon have access to GLP-1 medications, Zepbound and Wegovy, for an affordable cost of $50 per month.
This program is a result of an agreement between the drug manufacturers and the Trump administration.
Eligibility for these medications is restricted to overweight individuals with pre-diabetes, uncontrolled high blood pressure, or a history of stroke or cardiovascular disease.
Under the terms of the agreement, Medicare will pay $245 per month for each eligible recipient receiving these medications.
Approximately 10% of all Medicare recipients qualify for this benefit.
Click here to download our free news, weather and smart TV apps. And click here to stream Channel 9 Eyewitness News live.